Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public

Added by llasorsa
Group name EquipeMY
Item Type Journal Article
Title Synthetic Melanin Acts as Efficient Peptide Carrier in Cancer Vaccine Strategy
Creator Cuzzubbo et al.
Author Stefania Cuzzubbo
Author Guillaume Darrasse-Jčze
Author Benoit Hosten
Author Manon Leclercq
Author Nicolas Vignal
Author Claire Banissi
Author Eric Tartour
Author Antoine F. Carpentier
Abstract We previously reported that a novel peptide vaccine platform, based on synthetic melanin nanoaggregates, triggers strong cytotoxic immune responses and significantly suppresses tumor growth in mice. However, the mechanisms underlying such an efficacy remained poorly described. Herein, we investigated the role of dendritic cells (DCs) in presenting the antigen embedded in the vaccine formulation, as well as the potential stimulatory effect of melanin upon these cells, in vitro by coculture experiments and ELISA/flow cytometry analysis. The vaccine efficiency was evaluated in FLT3-L-/- mice constitutively deficient in DC1, DC2, and pDCs, in Zbtb46DTR chimera mice deficient in DC1 and DC2, and in LangerinDTR mice deficient in dermal DC1 and Langerhans cells. We concluded that DCs, and especially migratory conventional type 1 dendritic cells, seem crucial for mounting the immune response after melanin-based vaccination. We also assessed the protective effect of L-DOPA melanin on peptides from enzymatic digestion, as well as the biodistribution of melanin-peptide nanoaggregates, after subcutaneous injection using [18F]MEL050 PET imaging in mice. L-DOPA melanin proved to act as an efficient carrier for peptides by fully protecting them from enzymatic degradation. L-DOPA melanin did not display any direct stimulatory effects on dendritic cells in vitro. Using PET imaging, we detected melanin-peptide nanoaggregates up to three weeks after subcutaneous injections within the secondary lymphoid tissues, which could explain the sustained immune response observed (up to 4 months) with this vaccine technology.
Publication International Journal of Molecular Sciences
Volume 23
Issue 23
Pages 14975
Date 2022-11-29
Journal Abbr Int J Mol Sci
Language eng
DOI 10.3390/ijms232314975
ISSN 1422-0067
Library Catalog PubMed
Extra PMID: 36499300 PMCID: PMC9738778
Tags Animals, cancer vaccine, Cancer Vaccines, carrier, delivery system, Dendritic Cells, L-DOPA, Langerhans cells, melanin, Melanins, Mice, Mice, Inbred C57BL, Neoplasms, peptide vaccine, Peptides, Tissue Distribution
Date Added 2024/10/10 - 16:51:52
Date Modified 2024/10/10 - 16:51:52
Notes and Attachments PubMed entry (Attachment)
Texte intégral (Attachment)


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés